AC Immune’s (ACIU) Buy Rating Reiterated at BTIG Research

AC Immune (NASDAQ:ACIU)‘s stock had its “buy” rating reaffirmed by analysts at BTIG Research in a research report issued to clients and investors on Wednesday, Benzinga reports. They currently have a $8.00 target price on the stock. BTIG Research’s price target indicates a potential upside of 200.19% from the company’s previous close.

A number of other research analysts have also commented on ACIU. HC Wainwright reissued a “buy” rating on shares of AC Immune in a report on Monday, August 24th. Weiss Ratings reissued a “sell (e+)” rating on shares of AC Immune in a research note on Wednesday, August 5th. Three equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $7.50.

AC Immune Stock Performance

AC Immune stock traded down $0.17 during midday trading on Wednesday, reaching $2.67. 109,527 shares of the stock traded hands, compared to its average volume of 273,957. AC Immune has a fifty-two week low of $2.10 and a fifty-two week high of $4.00. The company has a current ratio of 0.93, a quick ratio of 1.02 and a debt-to-equity ratio of 0.11. The firm has a market cap of $271.22 million, a price-to-earnings ratio of -4.94 and a beta of 1.60. The firm has a fifty day moving average price of $2.55 and a two-hundred day moving average price of $2.68.

AC Immune (NASDAQ:ACIU) last issued its quarterly earnings data on Thursday, August 6th. The company reported $0.03 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.13. The business had revenue of $18.67 million during the quarter, compared to the consensus estimate of $9.59 million. AC Immune had a negative return on equity of 100.17% and a negative net margin of 245.32%. On average, equities research analysts forecast that AC Immune will post -0.6 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. AXQ Capital LP purchased a new position in shares of AC Immune during the 2nd quarter valued at $25,000. Dimensional Fund Advisors LP grew its position in shares of AC Immune by 82.8% in the first quarter. Dimensional Fund Advisors LP now owns 390,165 shares of the company’s stock valued at $1,071,000 after purchasing an additional 176,701 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership lifted its position in shares of AC Immune by 8.0% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 405,658 shares of the company’s stock worth $1,116,000 after purchasing an additional 30,035 shares during the last quarter. Hedge funds and other institutional investors own 51.36% of the company’s stock.

Key AC Immune News

Here are the key news stories impacting AC Immune this week:

• Positive Sentiment: Positive Phase 2 safety and immune-response data: Through week 100 of the VacSYn Phase 2 trial, ACI-7104 met all primary endpoints, was generally safe and well tolerated, and produced a 100% antibody response after three doses. Antibodies also penetrated the cerebrospinal fluid, with signals of target engagement—important evidence that the vaccine is reaching the central nervous system. AC Immune Phase 2 trial announcement
• Positive Sentiment: Analysts reaffirm bullish views: BTIG Research reiterated its Buy rating and set an $8 price target, implying substantial potential appreciation from the reference price of $2.71. H.C. Wainwright analyst Andrew Fein also maintained a Buy rating and $12 target, citing the VacSYn data as validation of AC Immune’s platform. BTIG Research rating H.C. Wainwright rating
• Neutral Sentiment: Development remains ongoing: The reported results primarily establish safety and immunogenicity, rather than demonstrating definitive clinical benefits for Parkinson’s patients. Part 2 of the trial is intended to assess clinical activity, and AC Immune expects to discuss the future development path with the FDA in early 2027. AC Immune Phase 2 results

About AC Immune

AC Immune SA (NASDAQ: ACIU) is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland. Founded in 2003, the company develops precision medicines and diagnostic products designed to prevent, diagnose and treat neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease and other conditions associated with misfolded proteins.

AC Immune’s research is based on its SupraAntigen and Morphomer technology platforms, which are intended to identify disease-related proteins and generate therapies or diagnostic tools that target them.